Patents by Inventor Pradeep K. Sharma

Pradeep K. Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240082275
    Abstract: This invention relates to a pharmaceutical composition comprising 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine as the active pharmaceutical ingredient, and therapeutic uses of the pharmaceutical formulation. In particular, the invention is directed to tablets comprising the pharmaceutical composition, methods of preparing the tablets, and therapeutic uses thereof.
    Type: Application
    Filed: November 14, 2023
    Publication date: March 14, 2024
    Inventors: Dauntel S. Verwijs, Samir Desai, Pradeep K. Sharma, Leonard W. Rozamus, Jeff Williamson, Danica Cartwright, Parag Ved
  • Publication number: 20240083902
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Application
    Filed: February 27, 2023
    Publication date: March 14, 2024
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Publication number: 20220249524
    Abstract: This invention relates to a pharmaceutical composition comprising 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine as the active pharmaceutical ingredient, and therapeutic uses of the pharmaceutical formulation. In particular, the invention is directed to tablets comprising the pharmaceutical composition, methods of preparing the tablets, and therapeutic uses thereof.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 11, 2022
    Inventors: Dauntel S. Verwijs, Samir Desai, Pradeep K. Sharma, Leonard W. Rozamus, Jeff Williamson, Danica Cartwright, Parag Ved
  • Patent number: 11384086
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: July 12, 2022
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Patent number: 11279705
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: March 22, 2022
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Publication number: 20210401860
    Abstract: This invention relates to a pharmaceutical composition comprising 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine as the active pharmaceutical ingredient, and therapeutic uses of the pharmaceutical formulation. In particular, the invention is directed to tablets comprising the pharmaceutical composition, methods of preparing the tablets, and therapeutic uses thereof.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 30, 2021
    Inventors: Dauntel S. Verwijs, Samir Desai, Pradeep K. Sharma, Leonard W. Rozamus, Jeff Williamson, Danica Cartwright, Parag Ved
  • Patent number: 11192895
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: December 7, 2021
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Patent number: 11192897
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: December 7, 2021
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Patent number: 11192896
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: December 7, 2021
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Publication number: 20210340149
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 4, 2021
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Publication number: 20210277011
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Application
    Filed: May 12, 2021
    Publication date: September 9, 2021
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Publication number: 20210277010
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Application
    Filed: May 12, 2021
    Publication date: September 9, 2021
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Publication number: 20210277012
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Application
    Filed: May 12, 2021
    Publication date: September 9, 2021
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Publication number: 20210186994
    Abstract: This invention relates to a pharmaceutical composition comprising 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine as the active pharmaceutical ingredient, and therapeutic uses of the pharmaceutical formulation. In particular, the invention is directed to tablets comprising the pharmaceutical composition, methods of preparing the tablets, and therapeutic uses thereof.
    Type: Application
    Filed: March 5, 2021
    Publication date: June 24, 2021
    Inventors: Dauntel S. Verwijs, Samir Desai, Pradeep K. Sharma, Leonard W. Rozamus, Jeff Williamson, Danica Cartwright, Parag Ved
  • Publication number: 20210024527
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Application
    Filed: May 22, 2020
    Publication date: January 28, 2021
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Patent number: 10662197
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 26, 2020
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Publication number: 20190169196
    Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
    Type: Application
    Filed: September 28, 2018
    Publication date: June 6, 2019
    Inventors: Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
  • Publication number: 20180256610
    Abstract: This invention relates to a pharmaceutical composition comprising 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine as the active pharmaceutical ingredient, and therapeutic uses of the pharmaceutical formulation. In particular, the invention is directed to tablets comprising the pharmaceutical composition, methods of preparing the tablets, and therapeutic uses thereof.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 13, 2018
    Inventors: Dauntel S. Verwijs, Samir Desai, Pradeep K. Sharma, Leonard W. Rozamus, Jeff Williamson, Danica Cartwright, Parag Ved
  • Publication number: 20100048920
    Abstract: Processes for preparing racemic mixtures of 5,7,3?,4?-tetra-O-benzyl-(±)-catechin and (±)-epicatechin involves (i) condensing 2-hydroxy-4,6-bis(benzyloxy)-acetophenone and 3,4-bis(benzyloxy)benzaldehyde, cyclizing the resulting compound, oxidizing the resulting compound; (ii) dihydroxylating (E)-3-(3?,4?-bis(benzyloxy)phenyl)prop-2-ene-1-ol and reducing the 1,2-diol; or (iii) coupling 3,5-bis(benzyloxy)phenol with (E)-3,5-bis(benzyloxy)-2-(3?,4?-bis(benzyloxy)phenyl)allyl)phenol and cyclizing the resulting chalcone. A process for preparing the benzylated epimers of catechin and epicatechin involves seven steps. 3,4-Bis(benzyloxy)benzaldehyde is coupled with 2-hydroxy-4,6-benzyloxy-acetophenone to form a chalcone. The chalcone is selectively reduced to an alkene. The phenolic group of the alkene is protected. The protected alkene is asymetrically dihydroxylated. The resulting compound is deprotected, cyclized, and finally hydrolyzed.
    Type: Application
    Filed: June 28, 2006
    Publication date: February 25, 2010
    Applicants: Mars, Incorporated, Johnson Matthey Pharmaceutical Materials, Inc.
    Inventors: Leo J. Romanczyk, JR., Pradeep K. Sharma, Daming Gou, Yanni Gou
  • Publication number: 20040049049
    Abstract: A stereoselectively method of preparing a 1,2-disubstituted cycloalkyl, such as aminocycloalkyl ether compounds, from a trans-1,2-disubstituted cycloalkyl or a cis-2-substituted cycloalkanol. For example, a stereoselective method of preparing 1R-(3R-hydroxypyrrolidin-1-yl)-2R-(2-phenylethoxy)-cyclohexane from 1R,2R-cyclohexanediol or from meso-cis-1,2-cyclohexanediol is described. Aminocycloalkyl ethers, such as 1R-(3R-hydroxypyrrolidin-1-yl)-2R-(2-phenylethoxy)-cyclohexane, can be used to treat cardiac disease.
    Type: Application
    Filed: June 10, 2003
    Publication date: March 11, 2004
    Applicant: Johnson Matthey Pharmaceutical Materials, Inc.
    Inventors: Jurjus F. Jurayj, Emile Farhan, Pradeep K. Sharma